Inflammation

As the population continues to diversify, the United States may be headed for increases in atopic dermatitis disease burden among children, said Jonathan Silverberg, MD, PhD, MPH.

As atopic dermatitis (AD) prevalence has increased in children over several decades, it's critical for physicians to recognize the environmental and demographic factors contributing to the change, said Jonathan Silverberg, MD, PhD, MPH.

The study findings show that atopic dermatitis is associated with internalizing and externalizing problems, with younger children experiencing emotional problems and adolescents with other atopic diseases having relationship problems.

Data from a recent cross-sectional study show severity of atopic dermatitis (AD) is associated with prevalence of learning disorders among children.

According to the researchers, the study is the first to describe a relationship between these factors and the development of atopic dermatitis (AD) in infants using multiomics.

Exposure to indoor formaldehyde can exacerbate atopic dermatitis (AD) symptoms in children with moderate to severe disease, especially in spring and summer and even at allowable levels.

Machine learning models can help predict which children diagnosed with childhood asthma before age 5 will continue to experience symptoms as they get older.

Deep learning algorithms to diagnose skin disease like atopic dermatitis could save time for providers while increasing accuracy, according to a pilot study.

Recent findings indicate that the symptoms of atopic dermatitis, hives, and rhinitis can all be linked to specific microbiota, implying that the gut-skin axis and gut-nose axis do exist.

The case illustrates how these 2 different conditions may share a related mechanism of action.

Although 90% of patients with severe asthma choose to continue using a biologic, patients with worse disease control at baseline or with lower socioeconomic status (SES) may be more likely to cease biologic use, according to a poster presented at the American Academy of Allergy, Asthma & Immunology 2021 Annual Meeting.

Use of a specialty pharmacy to take over the management of prior authorization (PA) requests for a dermatology practice significantly reduced the time to a decision and also decreased the time it took to fill the medication.

Treatment of asthma with biologics was lower for those on public health insurance compared with those who had private insurance, with Blacks underrepresented relative to Whites in publicly insured visits where biologic treatment is used.

Significant differences in health characteristics may provide insight into why females are far more likely to suffer asthma than males

Temperature and transepidermal water loss can serve as objective measures to help determine severity of cases of atopic dermatitis (AD) psoriasis and identify which patients need intensive treatment, according to a new study.

A recent review explores the use of biologics in atopic and inflammatory conditions as well as lingering research gaps.

Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.

A review explored the potential role of eosinophils and their mediators in the pathophysiology of chronic rhinosinusitis (CRS) subtypes.

Matthew J. Zirwas, MD, a dermatologist in Ohio, discusses how dermatologists may stratify patients with atopic dermatitis (AD) with the launch of new biologic treatments in 2021.

The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).

In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.

This year, the most popular articles and interviews related to the role of inflammation in asthma and other conditions touched on the mechanisms of inflammation, patterns of inhaler use, and the real-world impacts of the monoclonal antibody dupilumab.

The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.

The treatment landscape for atopic dermatitis is beginning to change from the use of topical therapies to biologics and more, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.

Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.